Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted? Feb 15, 2017
These Medical Instruments Won’t Heal Your Portfolio
The medical instruments industry is a group characterized in part by diversity, and as such, there are ideas of all shapes and sizes. Let’s dig into two overvalued companies in the space and what put them in their current positions. Jan 8, 2017
Looking Closely at Zimmer Biomet
Image Source: Zimmer Biomet. Medical technology companies have taken their share of lumps as of late, but the long-term may be too bright for investors to ignore Zimmer Biomet's shares. Jan 1, 2017
Dividend Increases/Decreases for the Week Ending December 30
Let's take a look at companies raising/lowering their dividends this week. Nov 23, 2016
Earnings Insight – Medtronic’s Free Cash Flow Story
Image Source: Medtronic. Let’s cover some ground on Medtronic’s calendar third-quarter report, its second-quarter fiscal 2017 results. Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. Dec 14, 2015
Dividend Increases/Decreases for the Week Ending December 11
Let's take a look at companies raising/lowering their dividends this week. Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings. Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space . Sep 26, 2013
MAKO Receives a Tremendous Offer from Stryker; Is Intuitive Surgical Next?
MAKO receives an offer from Stryker that was an 83% premium to its previous day's closing price. Let’s take a look at the deal and what it may mean for Intuitive Surgical. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
